Zomedica Corp. reported a revenue of $32.0 million for the fiscal year ending December 31, 2025, marking a 17% increase from $27.3 million in the previous year. The company's net loss widened to $81.9 million, compared to a loss of $47.0 million in 2024, primarily due to significant impairment charges totaling $55.8 million. These impairments were largely attributed to a decline in the company's market capitalization following its delisting from the NYSE American. The gross profit margin slightly decreased to 68% from 70% in the prior year, reflecting higher depreciation expenses and increased manufacturing costs.
In terms of operational developments, Zomedica has expanded its product portfolio through strategic acquisitions, including Structured Monitoring Products, Inc. and Qorvo Biotechnologies, LLC, which were completed in September and October 2023, respectively. These acquisitions are expected to enhance Zomedica's capabilities in veterinary diagnostics and monitoring technologies. The company has also launched several new products, including the VETGuardian Zero Touch vital signs monitoring system and the TRUVIEW digital microscopy platform, which are aimed at improving veterinary care and operational efficiency.
Zomedica's customer base has shown growth, with increased engagement metrics reported across its product lines. The company has focused on expanding its market presence, particularly in the U.S. and international veterinary markets. As of December 31, 2025, Zomedica employed 141 individuals, a slight increase from the previous year, reflecting its commitment to building a robust sales and marketing team to support its growth initiatives.
Looking ahead, Zomedica anticipates continued revenue growth driven by its expanding product offerings and increased sales efforts. The company plans to leverage its existing infrastructure to enhance product adoption rates and explore new market opportunities. However, Zomedica also cautions that it expects to incur losses in the near term as it invests in research and development and commercialization activities. The company remains focused on achieving profitability while navigating the challenges posed by market conditions and operational integration from its recent acquisitions.
About Zomedica Corp.
Zomedica Corp. is an animal health company developing and marketing diagnostic and therapeutic products for companion animals and horses. Its portfolio includes innovative diagnostics, digital microscopy, remote monitoring, and pain/inflammation treatment devices. Serving veterinarians and pet owners globally, Zomedica focuses on improving animal care, practice efficiency, and profitability through proprietary technologies, strategic acquisitions, and a diversified product pipeline.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.